CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+8.44%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$287M
AUM Growth
+$287M
(+14%)
Cap. Flow
+$29.6M
Cap. Flow
% of AUM
10.3%
Top 10 Holdings %
Top 10 Hldgs %
59.07%
Holding
34
New
3
Increased
15
Reduced
4
Closed
5
Top Buys
| 1 |
Celcuity
CELC
|
$20.9M |
| 2 |
Cytokinetics
CYTK
|
$13.9M |
| 3 |
Aclaris Therapeutics
ACRS
|
$11.3M |
| 4 |
MacroGenics
MGNX
|
$9.33M |
| 5 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$4.69M |
Top Sells
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$13.6M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$8.55M |
| 3 |
Protagonist Therapeutics
PTGX
|
$6.24M |
| 4 |
Relmada Therapeutics
RLMD
|
$5.69M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$5.29M |
Sector Composition
| 1 | Healthcare | 99.08% |
| 2 | Financials | 0.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Aclaris Therapeutics
ACRS
$209M
| $29.3M | 10.21% |
1,668,987
+640,903
| +62% | +$11.3M |
|
|
STSA
2
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $21.8M | 7.61% |
3,096,729
+665,024
| +27% | +$4.69M |
|
|
3
Celcuity
CELC
$2.17B
| $20.9M | 7.28% |
+870,967
| New | +$20.9M |
|
4
C4 Therapeutics
CCCC
$185M
| $18.2M | 6.34% |
481,094
| – | – |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $15.4M | 5.36% |
3,529,465
+545,952
| +18% | +$2.38M |
|
|
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $14.9M | 5.19% |
440,869
+72,421
| +20% | +$2.45M |
|
|
7
Cytokinetics
CYTK
$4.23B
| $13.9M | 4.86% |
+704,317
| New | +$13.9M |
|
8
Kura Oncology
KURA
$686M
| $13M | 4.51% |
621,493
+99,938
| +19% | +$2.08M |
|
9
Cogent Biosciences
COGT
$1.69B
| $11.1M | 3.86% |
1,367,582
+98,387
| +8% | +$798K |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $11M | 3.84% |
1,748,241
+19,200
| +1% | +$121K |
|
11
Celldex Therapeutics
CLDX
$1.47B
| $10.8M | 3.77% |
323,437
-46,514
| -13% | -$1.56M |
|
|
12
MacroGenics
MGNX
$112M
| $10.6M | 3.69% |
393,850
+347,220
| +745% | +$9.33M |
|
13
VistaGen Therapeutics
VTGN
$102M
| $10.5M | 3.66% |
3,331,315
-398,379
| -11% | -$1.25M |
|
|
14
Protagonist Therapeutics
PTGX
$3.67B
| $9.45M | 3.29% |
210,600
-139,000
| -40% | -$6.24M |
|
15
ESSA Pharma
EPIX
$11.4M
| $8.05M | 2.81% |
281,911
+105,090
| +59% | +$3M |
|
|
KRON
16
DELISTED
Kronos Bio
KRON
| $7.16M | 2.49% |
298,839
| – | – |
|
|
GNCA
17
DELISTED
Genocea Biosciences, Inc.
GNCA
| $6.86M | 2.39% |
2,929,447
+57,823
| +2% | +$135K |
|
|
MREO
18
Mereo BioPharma
MREO
$272M
| $6.53M | 2.27% |
2,059,729
+10,972
| +0.5% | +$34.8K |
|
19
Dyne Therapeutics
DYN
$1.92B
| $6.42M | 2.24% |
305,125
-124,987
| -29% | -$2.63M |
|
20
Xenon Pharmaceuticals
XENE
$2.98B
| $6.08M | 2.12% |
326,336
+24,944
| +8% | +$464K |
|
21
Mersana Therapeutics
MRSN
$36.5M
| $5.83M | 2.03% |
429,228
| – | – |
|
22
KalVista Pharmaceuticals
KALV
$678M
| $5.43M | 1.89% |
226,671
+12,204
| +6% | +$292K |
|
23
PMV Pharmaceuticals
PMVP
$74.2M
| $4.27M | 1.49% |
125,000
| – | – |
|
|
IVA
24
Inventiva
IVA
$861M
| $3.58M | 1.25% |
262,658
| – | – |
|
25
Seres Therapeutics
MCRB
$166M
| $3.47M | 1.21% |
145,453
+4,150
| +3% | +$99K |
|